When was Ossium Health founded?

Ossium Health was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Ossium Health located?

Ossium Health is headquartered in San Francisco, United States.

Who is the current CEO of Ossium Health?

Kevin Caldwell of Ossium Health. They have also founded 1 company.

How many employees does Ossium Health have?

As of Aug 31, 2026, the latest employee count at Ossium Health is 107.

Is Ossium Health a funded company?

Ossium Health is a funded company, having raised a total of $125M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 18, 2016.

When was the latest funding round of Ossium Health?

Ossium Health's latest funding was a $***** Grant (prize money) round on Sep 02, 2025, with participation from 1 investor.

Where does Ossium Health rank among its competitors?

Ossium Health ranks 2nd amongst 115 active competitors, of which 42 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was CERo Therapeutics, which secured $750K in May, 2026.

Who are the top competitors of Ossium Health?

Ossium Health's top competitors include MaaT Pharma, Cellino and Rigel. Among them, CERo Therapeutics secured the most recent funding round in May, 2026.

Ossium Health - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning. The lead product, HPC, Marrow is a cell therapy product derived from HLA-matched hematopoietic progenitor cell (HPC) of bone marrow. These cells can be used for hematopoietic reconstitution for patients suffering from blood cancers including leukemia. Other products under development are CHIMERA is for improving organ transplantation and CHYMALIS is a cell therapy derived from mesenchymal stem cells (MSCs) from bone marrow for tissue damage healing & radiation poisoning. The company also provides bone marrow (BM) cells for labs doing research in oncology, immunology, etc.

Website: ossiumhealth.com
Email ID: *****@ossiumhealth.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

San Francisco, United States

Stage

Series C

Total Funding

$125M in 13 rounds

Latest Funding Round

Grant (prize money), Sep 02, 2025, $*****

Investors

General Catalyst & 13 more

Ranked

2^nd among 115 active competitors

Employee Count

107 as on Aug 31, 2026

Similar Companies

MaaT Pharma & 119 more

View Ossium Health's full profile

Ossium Health has raised a total funding of $125M over 13 rounds. Its first funding round was on Aug 18, 2016. Its latest funding round was a Grant (prize money) round on Sep 02, 2025 for $*****. 1 investor participated in its latest round. Ossium Health has 13 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Ossium Health:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 02, 2025	7527687	Grant (prize money)	4439961	9176319	3159661	1560055
Aug 14, 2024	4646766	Grant (prize money)	8318065	6246683	8585402	HHS
Jul 25, 2023	9225595	Series C	5720297	6436617	CPMG	Vivo Capital & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Ossium Health's funding rounds and investors

The founders of Ossium Health are Sebastian Eriksson Giwa and Kevin Caldwell. Kevin Caldwell is the CEO of Ossium Health.

Here are the details of Ossium Health's key team members:

Sebastian Eriksson Giwa: Former Co-Founder of Ossium Health.
Kevin Caldwell: Co-Founder & CEO of Ossium Health.
Contact Info: 1 email address

View details of Ossium Health's Founder profiles and Board Members

Ossium Health's employee count trend

Ossium Health has 107 employees as of Aug 26. Here is Ossium Health's employee count trend over the years:

Uncover Ossium Health's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ossium Health include MaaT Pharma, Cellino and Rigel. Here is the list of Top 10 competitors of Ossium Health, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, Symbiosis & 11 others	65/100
2nd	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	General Catalyst, XYZ Venture Capital & 12 others	65/100
3rd	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Humboldt Fund, Khosla Ventures & 7 others	65/100
4th	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MPM Capital, MidCap Financial & 6 others	64/100
5th	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	64/100
6th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
7th	Adicet Bio 2014, Menlo Park (United States), Public	Developer of immune cell therapeutic solutions for the treatment of cancer	$51M	Consensus Business Group, Handok & 18 others	61/100
8th	CERo Therapeutics 2016, San Francisco (United States), Public	Developer of platforms for cellular immunotherapy	$54.8M	SRx Health, Arch Venture Partners & 1 others	58/100
9th	StemlineTherapeutics 2003, New York City (United States), Acquired	Oncology therapeutics innovator focused on transforming cancer patient lives	$15.1M	Avoro Capital, Great Point Partners & 1 others	58/100
10th	Charm Therapeutics 2021, London (United Kingdom), Series B	Developer of menin inhibitors designed for acute myeloid leukemia treatment	$150M	Orbimed, F-Prime Capital & 11 others	58/100